Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2014-09-15 Investor Presentation
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Investor Presentation 26 pages 3.6MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation 16 September 2014' and contains detailed information about the company's immuno-oncology products, leadership, scientific advisory board, clinical status, and market positioning. It includes disclaimers typical of investor presentations and focuses on business strategy, product pipeline, and investment rationale rather than financial statements or regulatory filings. There is no indication that this is an annual report, earnings release, or regulatory filing. The length (15,000 characters) and content are consistent with a detailed investor presentation. Therefore, the document is best classified as an Investor Presentation (IP).
2014-09-15 English
Swiss Drug Manufacturer to Speed Her-Vaxx Development 1
Capital/Financing Update Classification · 70% confidence The document is a press release announcing that Imugene has signed a Swiss drug manufacturer to accelerate the development of Her-Vaxx. The content is a corporate announcement about a partnership or development collaboration, not a financial report, regulatory filing, or meeting material. The document length is short (2773 characters) and does not contain financial data, regulatory references, or meeting information. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is Capital/Financing Update (CAP) as it relates to a development partnership that could impact company financing or capital structure indirectly, but since it is more of a corporate announcement about a development collaboration, the closest category is CAP rather than others. Confidence is moderate due to limited content but clear corporate announcement nature.
2014-09-14 English
Research Agreement with Medical University of Vienna 1
Regulatory Filings Classification · 95% confidence The document is a press release announcing a research agreement for pre-clinical peptide analysis to support upcoming clinical trials. It does not contain financial data, regulatory filings, or detailed financial reports. It is not an announcement of voting results, management changes, or capital updates. It is a corporate announcement related to research collaboration and clinical trial preparation. Given the content and length (2803 characters), it fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2014-09-07 English
Investor Newsletter 4 pages 929.3KB
Investor Presentation Classification · 95% confidence The document is titled 'INVESTOR UPDATE ISSUE 3' and contains detailed information about the company's new CEO, clinical trial progress, manufacturing updates, and upcoming shareholder presentations. It includes background on management, scientific updates, and invitations to investor briefings. The document is lengthy (over 14,000 characters) and provides substantive company and operational updates rather than just a brief announcement or a transcript. It does not contain financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It is not a transcript of a call, nor an audit or legal report. The focus is on management updates, company strategy, and investor relations, including CEO introduction and business direction. This aligns best with an Investor Presentation (IP) or an Investor Update document. Given the detailed narrative and strategic content aimed at investors, the classification as Investor Presentation (IP) is most appropriate with high confidence.
2014-08-27 English
Appendix 4E and Annual Financial Report 71 pages 1.0MB
Annual Report Classification · 100% confidence The document is titled 'Appendix 4E – Preliminary Final Report' and references ASX Listing Rule 4.2A, indicating it is a financial report for the year ended 30 June 2014. It includes detailed financial results, directors' report, auditor's independence declaration, corporate governance statement, and full financial statements including profit and loss, financial position, cash flows, notes, directors' declaration, and independent audit report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. The content includes comprehensive financial data, operational review, acquisitions, board changes, and risk factors, consistent with an Annual Report. Therefore, this document is an Annual Report (10-K equivalent) for the fiscal year ended 30 June 2014. FY 2014
2014-08-27 English
Charles Walker appointed Imugene CEO 2 pages 124.9KB
Board/Management Information Classification · 95% confidence The document announces the appointment of Charles Walker as CEO of Imugene Limited, detailing his background, the terms of his employment, and the company's business focus. There is no financial data, no report or presentation attached, and no mention of shareholder votes or regulatory filings. The content is about a change in senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 4525 characters, which is sufficient for a detailed announcement but not a full report. Confidence is high given the clear focus on management appointment.
2014-08-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.